July 13, 2012
Glenis Wilmott, MEP, leader of the UK Labour Group in the European Parliament has posted a blog here on the GlaxoSmithKline fraud case.
I will look at this case myself more closely in a future blog (I’m on holidays in Ireland at present). It has implications for the regulation and reporting of clinical trials, as have the many other cases of non-disclosure that have led to many billions of dollars in fines and penalties in the US over the past ten years.
(I had expected the Commission to have published a few days ago their proposals for the revision of the Clinical Trials Directives but there seems to be a delay.)Jim Murray
BioTech, Consumers, English, Ethics in Business, EU Institutions, EU Priorities, Health, Health & Lifestyle, Innovation and Growth, Medicines, Pharmaceuticals, Public Affairs, Science & Research, Uncategorized